A method for the diagnosis or prognosis of Alzheimer's disease (AD), includes the steps of placing a sample isolated from a person suspected of having AD onto a substrate labeling the sample to identify at least one epigenetic marker and/or genetic variation and determining a state of AD. One of the epigenetic markers is PM20D1 promoter DNA methylation and/or one of the genetic variation is in at least one of PM20D1 mQTL-associated SNPs. PM20D1 is used as a therapeutic target and viral vectors encoding PM20D1 are used in the therapy of AD. Moreover, a kit for diagnosing AD includes reagents for detecting the SNPs rs708727, rs947211, rs708730, rs708724 or rs823130.
Rakesh Chawla, Andrea Rizzi, Matthias Finger, Federica Legger, Matteo Galli, Sun Hee Kim, Jian Zhao, João Miguel das Neves Duarte, Tagir Aushev, Hua Zhang, Alexis Kalogeropoulos, Yixing Chen, Tian Cheng, Ioannis Papadopoulos, Gabriele Grosso, Valérie Scheurer, Meng Xiao, Qian Wang, Michele Bianco, Varun Sharma, Joao Varela, Sourav Sen, Ashish Sharma, Seungkyu Ha, David Vannerom, Csaba Hajdu, Sanjeev Kumar, Sebastiana Gianì, Kun Shi, Abhisek Datta, Siyuan Wang, Anton Petrov, Jian Wang, Yi Zhang, Muhammad Ansar Iqbal, Yong Yang, Xin Sun, Muhammad Ahmad, Donghyun Kim, Matthias Wolf, Anna Mascellani, Paolo Ronchese, , , , , , , , , , , , , , , , , , , , , , , ,